Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mitigation of Ionizing Radiation-Induced Gastrointestinal Damage by Insulin-Like Growth Factor-1 in Mice

J. Pejchal, A. Tichy, A. Kmochova, L. Fikejzlova, K. Kubelkova, M. Milanova, A. Lierova, A. Filipova, L. Muckova, J. Cizkova

. 2022 ; 13 (-) : 663855. [pub] 20220629

Language English Country Switzerland

Document type Journal Article

Purpose: Insulin-like growth factor-1 (IGF-1) stimulates epithelial regeneration but may also induce life-threatening hypoglycemia. In our study, we first assessed its safety. Subsequently, we examined the effect of IGF-1 administered in different dose regimens on gastrointestinal damage induced by high doses of gamma radiation. Material and methods: First, fasting C57BL/6 mice were injected subcutaneously with IGF-1 at a single dose of 0, 0.2, 1, and 2 mg/kg to determine the maximum tolerated dose (MTD). The glycemic effect of MTD (1 mg/kg) was additionally tested in non-fasting animals. Subsequently, a survival experiment was performed. Animals were irradiated (60Co; 14, 14.5, or 15 Gy; shielded head), and IGF-1 was administered subcutaneously at 1 mg/kg 1, 24, and 48 h after irradiation. Simultaneously, mice were irradiated (60Co; 12, 14, or 15 Gy; shielded head), and IGF-1 was administered subcutaneously under the same regimen. Jejunum and lung damage were assessed 84 h after irradiation. Finally, we evaluated the effect of six different IGF-1 dosage regimens administered subcutaneously on gastrointestinal damage and peripheral blood changes in mice 6 days after irradiation (60Co; 12 and 14 Gy; shielded head). The regimens differed in the number of doses (one to five doses) and the onset of administration (starting at 1 [five regimens] or 24 h [one regimen] after irradiation). Results: MTD was established at 1 mg/kg. MTD mitigated lethality induced by 14 Gy and reduced jejunum and lung damage caused by 12 and 14 Gy. However, different dosing regimens showed different efficacy, with three and four doses (administered 1, 24, and 48 h and 1, 24, 48, and 72 h after irradiation, respectively) being the most effective. The three-dose regimens supported intestinal regeneration even if the administration started at 24 h after irradiation, but its potency decreased. Conclusion: IGF-1 seems promising in the mitigation of high-dose irradiation damage. However, the selected dosage regimen affects its efficacy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023813
003      
CZ-PrNML
005      
20221031095154.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2022.663855 $2 doi
035    __
$a (PubMed)35847048
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
245    10
$a Mitigation of Ionizing Radiation-Induced Gastrointestinal Damage by Insulin-Like Growth Factor-1 in Mice / $c J. Pejchal, A. Tichy, A. Kmochova, L. Fikejzlova, K. Kubelkova, M. Milanova, A. Lierova, A. Filipova, L. Muckova, J. Cizkova
520    9_
$a Purpose: Insulin-like growth factor-1 (IGF-1) stimulates epithelial regeneration but may also induce life-threatening hypoglycemia. In our study, we first assessed its safety. Subsequently, we examined the effect of IGF-1 administered in different dose regimens on gastrointestinal damage induced by high doses of gamma radiation. Material and methods: First, fasting C57BL/6 mice were injected subcutaneously with IGF-1 at a single dose of 0, 0.2, 1, and 2 mg/kg to determine the maximum tolerated dose (MTD). The glycemic effect of MTD (1 mg/kg) was additionally tested in non-fasting animals. Subsequently, a survival experiment was performed. Animals were irradiated (60Co; 14, 14.5, or 15 Gy; shielded head), and IGF-1 was administered subcutaneously at 1 mg/kg 1, 24, and 48 h after irradiation. Simultaneously, mice were irradiated (60Co; 12, 14, or 15 Gy; shielded head), and IGF-1 was administered subcutaneously under the same regimen. Jejunum and lung damage were assessed 84 h after irradiation. Finally, we evaluated the effect of six different IGF-1 dosage regimens administered subcutaneously on gastrointestinal damage and peripheral blood changes in mice 6 days after irradiation (60Co; 12 and 14 Gy; shielded head). The regimens differed in the number of doses (one to five doses) and the onset of administration (starting at 1 [five regimens] or 24 h [one regimen] after irradiation). Results: MTD was established at 1 mg/kg. MTD mitigated lethality induced by 14 Gy and reduced jejunum and lung damage caused by 12 and 14 Gy. However, different dosing regimens showed different efficacy, with three and four doses (administered 1, 24, and 48 h and 1, 24, 48, and 72 h after irradiation, respectively) being the most effective. The three-dose regimens supported intestinal regeneration even if the administration started at 24 h after irradiation, but its potency decreased. Conclusion: IGF-1 seems promising in the mitigation of high-dose irradiation damage. However, the selected dosage regimen affects its efficacy.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tichy, Ales $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
700    1_
$a Kmochova, Adela $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
700    1_
$a Fikejzlova, Lenka $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
700    1_
$a Kubelkova, Klara $u Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
700    1_
$a Milanova, Marcela $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
700    1_
$a Lierova, Anna $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
700    1_
$a Filipova, Alzbeta $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
700    1_
$a Muckova, Lubica $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
700    1_
$a Cizkova, Jana $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, Brno, Czechia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 13, č. - (2022), s. 663855
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35847048 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095152 $b ABA008
999    __
$a ind $b bmc $g 1854033 $s 1175101
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c - $d 663855 $e 20220629 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20221010

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...